ReviewJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2013
Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively.
Review in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03038997 (Early Detection of Cardiac Toxicity in Childhood Cancer Survivors), which is not on this map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Detection of Cardiac Toxicity in Childhood Cancer Survivors
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Guideline
- Cardiac Manifestations ofHealth science reports · 2026Review
- Predicting cardiotoxicity in drug development: A deep learning approach.Journal of pharmaceutical analysis · 2025Article
- Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy.Experimental hematology & oncology · 2025Review
- Cardiac events among a cohort of 17,389 patients receiving cancer chemotherapy: short and long term implications.Cardio-oncology (London, England) · 2024Article
- Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines.Children (Basel, Switzerland) · 2024Review
- The role of stress echocardiography in identifying cardiotoxicity: an in-depth exploration.Frontiers in cardiovascular medicine · 2024Review
- Changes in vascular function and correlation with cardiotoxicity in women with newly diagnosed breast cancer undergoing HER2-directed therapy with and without anthracycline/cyclophosphamide.European heart journal open · 2024Article
- Progress in the Use of Echocardiography in Patients with Tumors.Reviews in cardiovascular medicine · 2024Review
- Detection and quantification of myocardial scar and LVEF with high efficiency digital SPECT: The expanding value proposition for clinical cardiology.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Challenges in Cardiovascular Imaging in Women with Breast Cancer.Current cardiology reports · 2023Review
- How equilibrium radionuclide angiography can quantify tricuspid regurgitation.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- The mRNA expression ofMolecular medicine reports · 2021Article
- Looking for trouble: Reduced myocardial flow reserve following anthracyclines.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- The Preventive role of Regular Physical Training in Ventricular Remodeling, Serum Cardiac Markers, and Exercise Performance Changes in Breast Cancer in Women Undergoing Trastuzumab Therapy-An REH-HER Study.Journal of clinical medicine · 2020Article
- Effects of physical exercise on outcomes of cardiac (dys)function in women with breast cancer undergoing anthracycline or trastuzumab treatment: study protocol for a systematic review.Systematic reviews · 2019Article
- Detection of chemotherapy-induced cardiotoxicity with antimyosin pretargeted imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Imaging doxorubicin and polymer-drug conjugates of doxorubicin-induced cardiotoxicity with bispecific anti-myosin-anti-DTPA antibody and Tc-99m-labeled polymers.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Early Detection and Monitoring of Cancer Chemotherapy-Related Left Ventricular Dysfunction by Imaging Methods.Arquivos brasileiros de cardiologia · 2019Review
- Cardio-oncology: Understanding cardiotoxicity to guide patient focused imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of cardio-oncology is challenged to address an ever greater spectrum of cardiotoxicity associated with combination chemotherapy, greater dose intensity, extremes of age, and enhanced patient survival which exposes more protracted risk of developing congestive heart failure (CHF). Recent reports of chemotherapy-induced hypertension as a common adverse effect of angiogenesis inhibitors and immunosuppressants clarify the need for routine blood pressure (BP) monitoring and guideline-based management of hypertension as an integral strategy to preserve LV function. Serial monitoring of radionuclide left ventricular ejection fraction (LVEF) in adults and echocardiography in children continues to provide outcome based, cost-effective prevention of CHF in high risk patients receiving chemotherapy. To optimize treatment and monitoring strategies to eliminate late-onset LV dysfunction and CHF, traditional and novel candidate methods for assessment of chemotherapy-induced LV dysfunction are reviewed. These include serial assessment of LV volume indices by gated SPECT ERNA and gated SPECT MPI, 3D echocardiography and contrast 2D echocardiography; longitudinal strain imaging, diastolic functional parameters, (123)I-MIBG, (111)In-Antimyosin antibody imaging, and (99m)Tc-Annexin V apoptosis imaging, biomarkers including troponins and BNP; genetic markers, and both functional and tissue characterization techniques with T1 weighted and T2 weighted images with cardiac magnetic resonance imaging (CMR). In our quest to optimize strategies for long-term cancer survival and prevention of CHF for patients receiving chemotherapy, rigorous modality and guideline-specific clinical outcome trials are required. A new multi-modality monitoring approach is proposed, which integrates evidence-based strengths of CMR, echocardiography, ERNA, biomarkers, and BP management for surveillance and validation of cardiotoxicity and prevention of clinical heart failure in patients receiving a broad spectrum of cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.